Scythian Biosciences (TSXV:SCYB) announced a Colombian based company it is in the process of acquiring, ColCanna SAS, obtained a cultivation and importation of non-psychoactive cannabis license.
As quoted in the press release:
Additionally, ColCanna has entered into an exclusive international supply agreement for Colombia (the “Supply Agreement”) with Aphria Inc. (TSX:APH) (“Aphria”), a prominent Canadian low-cost producer of medical cannabis.
Under the terms of the Supply Agreement, Aphria will supply ColCanna with cannabis products for research and development purposes as well as distribution to hospitals, retail pharmacies, and private health providers in Colombia’s public health system.
“Through the expansion of our partnership with Aphria, it is with great pleasure that I announce our entry into the Colombia market as the first supplier of Aphria’s pharma grade medicinal CBD oil in the country,” said CEO Rob Reid. “As we work to finalize the acquisition of ColCanna, we are eager to work hand and hand with Aphria to establish ColCanna as an international supplier of research-backed cannabis products.”
Click here to read the full press release.
The post Scythian Shares Update from Operations in Colombia appeared first on Investing News Network.